Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Korean College of Neuropsychopharmacology full text link Korean College of Neuropsychopharmacology Free PMC article
Full text links

Actions

Review
.2018 Nov 30;16(4):361-375.
doi: 10.9758/cpn.2018.16.4.361.

Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis

Affiliations
Review

Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis

Seon-Cheol Park et al. Clin Psychopharmacol Neurosci..

Abstract

We aimed to compare the efficacy and safety of long-acting injectable (LAI) and oral second-generation antipsychotics (SGAs) in treating schizophrenia by performing a systematic review and meta-analysis. MEDLINE, EMBASE, PsycINFO, CINAHL, and the Cochrane Library, as well as five Korean databases, were systemically searched to identify studies published from 2000 to 16 April 2015, which compared the efficacy and safety of LAI and oral SGAs. Using data from randomized controlled trials (RCTs), meta-analyses were conducted. In addition, the GRADE (the Grading of Recommendations, Assessment, Development and Evaluation) approach was applied to explicitly assess the quality of the evidence. A total of 30 studies including 17 RCTs and 13 observational studies were selected. The group treated with LAI SGAs was characterized by significantly lower relapse rates, longer times to relapse and fewer hospital days, but also by a higher occurrence of extrapyramidal syndrome and prolactin-related symptoms than that in the group treated with oral SGAs. Our findings demonstrate that there is moderate to high level of evidence suggesting that in the treatment of schizophrenia, LAI SGAs have higher efficacy and are associated with higher rates of extrapyramidal syndrome and prolactin-related symptoms. Additionally, the use of LAI SGAs should be combined with appropriate measures to reduce dopamine D2 antagonism-related symptoms.

Keywords: Efficacy; Long-acting injectable; Safety; Schizophrenia; Second-generation antipsychotics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Disposition of the selected articles for a systemic review and meta-analysis. KMBASE, Korean Medicine Database; KISS, Korean Studies Information Service System; RISS, the Research Information Sharing Service; NDSL, National Digital Science Library (NDSL); LAI, long-acting injectable.
See this image and copyright information in PMC

References

    1. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health. Nature. 2011;475:27–30. doi: 10.1038/475027a. - DOI - PMC - PubMed
    1. Kim YK, Choi J, Park SC. A novel bio-psychosocial-behavioral treatment model in schizophrenia. Int J Mol Sci. 2017;18:E734. doi: 10.3390/ijms18040734. - DOI - PMC - PubMed
    1. Karadag F, Sengul CB, Enli Y, Karakulah K, Alacam H, Kaptanoglu B, et al. Relationship between serum bilirubin levels and metabolic syndrome in patients with schizophrenia spectrum disorders. Clin Psychopharmacol Neurosci. 2017;15:153–162. doi: 10.9758/cpn.2017.15.2.153. - DOI - PMC - PubMed
    1. Tripathi A, Kar SK, Shukla R. Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci. 2018;16:7–17. doi: 10.9758/cpn.2018.16.1.7. - DOI - PMC - PubMed
    1. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41:1203–1211. - PubMed

Publication types

LinkOut - more resources

Full text links
Korean College of Neuropsychopharmacology full text link Korean College of Neuropsychopharmacology Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2026 Movatter.jp